Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), a fully integrated commercial biotechnology company focused on central nervous system (CNS) and immunology treatments, announced that its management team will participate in two upcoming investor conferences in May 2026. The company will attend the RBC Capital Markets Global Healthcare Conference on May 19 in New York and A.G.P.’s Annual Virtual Healthcare Conference on May 20, providing opportunities to present its commercial portfolio and pipeline developments to the investment community.
This announcement comes on the heels of significant progress for Tonix, including the recent approval of TONMYA (cyclobenzaprine HCl sublingual tablets 2.8mg), the first new treatment for fibromyalgia in over 15 years. The company’s CNS commercial infrastructure also supports its acute migraine products, Zembrace SymTouch and Tosymra. Beyond its commercial offerings, Tonix is exploring the potential of TONMYA in Phase 2 clinical trials for major depressive disorder and acute stress disorder, aiming to address high unmet needs in mental health.
The company’s pipeline extends into rare diseases and immunology. TNX-2900, a Phase 2-ready candidate for Prader-Willi syndrome, targets a rare genetic disorder. In immunology, Tonix is advancing TNX-4800, a monoclonal antibody for Lyme disease prophylaxis, and TNX-1500, a third-generation CD40 ligand inhibitor for preventing kidney transplant rejection. These programs underscore the company’s commitment to addressing critical health challenges through innovative science.
Investor conferences serve as a platform for Tonix to articulate its strategic vision and milestones. The company’s participation in these events is expected to draw attention from analysts and investors seeking insights into its commercial trajectory and pipeline advancements. The full press release detailing the conferences is available at https://ibn.fm/ZZpG2.
Tonix’s dual focus on CNS and immunology positions it uniquely in the biotech landscape. With a recently approved product and multiple candidates in clinical stages, the company aims to leverage its integrated infrastructure to drive growth and innovation. The upcoming conferences will provide a forum for management to discuss these developments and their implications for shareholders.
